Excision BioTherapeutics

One-time CRISPR cure for viral disease

Watertown, MA, US

Excision BioTherapeutics is a clinical-stage biotechnology company developing CRISPR-based gene-editing therapies to cure chronic viral infectious diseases by permanently eliminating viral DNA from infected cells.

Shareable draft

Check out Excision BioTherapeutics on @MedStartr Today Excision BioTherapeutics is a clinical-stage biotechnology company developing CRISPR-based gene-editing therapies to cure chronic viral infectious diseases by permanently eliminating viral DNA from infected cells. #InfectiousDiseases #MentalBehavioralHealth #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/J94H_kGXfQg

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Get Involved in Excision BioTherapeutics

1 engagement

Problem Statement

Current treatments for chronic viral infectious diseases only manage symptoms and do not offer a cure, requiring lifelong therapy for patients.

Core Technology

CRISPR systems

Key Differentiators

Proprietary 'dual cut approach' to excise viral DNA from infected cells.

Clinical Focus

Infectious Disease; Virology

Company Info

Business Model: B2B
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.excision.bio

Disease Areas

Infectious Diseases Mental Health

Technologies

CRISPR-Cas9CRISPR-CasXNucleaseGene Editing & CRISPR

Clinical & IP

🔬

Clinical Validation

Phase 1/2 trial completed (5 patients); FDA Fast Track designation; met safety and biodistribution endpoints; HSV and HBV data presented at ASGCT 2025

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Excision BioTherapeutics?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.